GREY:ATBPF - Post by User
Post by
Alex1967on Dec 07, 2020 5:25pm
495 Views
Post# 32054418
Zacks Investment Research - ATE upgareded to $28/share
Zacks Investment Research - ATE upgareded to $28/shareAntibe continues to execute on its strategy as it moves otenaproxesul toward initiation ofa global Phase 3 program. We anticipate an IND filing and an ‘End of Phase 2’meeting to occur during the first half of 2021 such that the first Phase 3 clinical trial can initiate by the end of the second quarter of 2021, withsubsequent trials initiating over the subsequent months. We are looking forward to continued updates as the company meets with regulatory authorities in preparation for the Phase 3 program. We have adjusted our model to account for the recent 1:10 share consolidation and our valuation is CAD$28.00 per share